After the pathogenic Microbiology laboratory passed the BSL-2 registration certification, on January 3, 2024, the Yuanvore Medicine Stem Cell Engineering Technology Center was officially opened, and the unveiling ceremony was held at the same time. This marks that the company's iPSC technology independent innovation platform is accelerating the construction, and will also help the development and application of stem cell therapy and regenerative medicine technology to make new breakthroughs.

Yuanvore Medicine Stem Cell Engineering Technology Center covers a total area of 1200 square meters, including biochemical, physical and chemical, PCR laboratories, pathogenic microbiology laboratories, as well as primary cell rooms, cell laboratories and stem cell banks with 10,000 cleanliness standards, which can meet the needs of cell reprogramming, gene editing, cell engineering transformation, drug quality control and testing. The official opening of the technology center has laid a solid foundation for the company to build iPSC reprogramming process platform, iPSC directional differentiation technology platform, iPSC genetic engineering transformation platform.

In the wave of the development of regenerative medicine, Yuanvore Medicine will continue to innovate and explore, to treat clinically unmet chronic degenerative diseases as the core research and development products, committed to providing patients around the world with reliable quality, affordable iPSC clinical drugs and large health consumer products.